Seven alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

[6] When RASSF1A is epigenetically inactivated, it leads to microtubule instability, suppression of apoptosis, and cell cycle progression, which promotes tumorigenesis.

[13] A few studies have been done to investigate the relationship between cervical cancers and RASSF1A, an isoform of RASSF1 that has been shown to suppress the proliferation in tumor cells.

[14] Through these studies, it was found that RASSF1A is commonly inactivated in adenocarcinomas (ACs) due to hypermethylation of the promoter region.

Through these studies, it was indicated that RASSF1A expression could induce apoptosis and regulate proliferation to suppress tumors, making it a potential therapeutic mechanism for cervical cancers.

[14] Aberrant methylation of RASSF1A has also been found in breast, lung, gastric, liver, and colorectal cancer.